Acquired Resistant Mechanism of the First-generation EGFR TKIs
Non-small Cell Lung CancerAquired Resistance1 morePatients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable genetic mutations can be helpful for guiding the subsequent treatment. This study aimed to analyze the genetic profile of NSCLC harboring acquired resistance to the first-generation EGFR TKIs using next generation sequencing (NGS).
The Role of Microbiota on the Development of Lung Cancer
NSCLCStage I6 moreRelationship between human microbiota and epidemiology of lung cancer
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
CarcinomaNon-small-cell Lung Cancer1 moreConduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring...
Non-small-cell Lung CarcinomaThe purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2~7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.
Gene Mutations in Non-Small Cell Lung Cancer Cells
CarcinomaNon-Small-Cell LungTo compare the frequency of individual genetic abnormality between tumor cells and blood specimens.
Establishment and Characterization of Patient-Derived Non-Small Cell Lung Cancer Xenografts and...
Non Small Cell Lung CancerXenografts and cell cultures provide sufficient material for analyses at the protein, RNA and DNA level. Patient derived NSCLC xenografts and cell lines are available but none however are Asian in origin. Given the emerging evidence to suggest inter-ethnic differences in NSCLC biology, new models of preclinical drug evaluation should be designed and validated using Asian tumors. Furthermore, such models will allow studies of biological mechanisms of sensitivity and/or resistance and also the study of dynamic regulations under standardized conditions in the Asian context.
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV...
Non Small Cell Lung CarcinomaThe primary aim of this non interventional study is to assess the independent prognostic role on overall survival of primary tumour 18F-FDG uptake value (SUVmax) measured on 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in patients with non-metastatic non-small cell lung cancers treated with curative intent, taking into account the other conventional prognostic factors (performance status, age, sex, disease stage).
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC)...
Non-Small Cell Lung CancerRecently it has been suggested that specific mutations in the EGFR gene in lung cancer patients is associated with response to a novel drug targeting the EGF system. Recent research also indicates that there is a possible association to the degree of aggressiveness of the disease. The importance of these mutations is controversial, because the data are based on small studies with highly selected patients. In this project the investigators want to study the types and frequencies of EGFR mutations in both untreated and treated patients in a systematic manner and relate this to survival. The thorough registration of patient data in DK enables us to create a strong The investigators expect this knowledge to be of greatest importance for future rational use of drugs targeting the EGF receptors.
CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology
Nonsmall Cell Lung CancerLung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually. Lung cancer is divided into two main groups: Small Cell Lung Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC), with prevalence of ~20% and 80% respectively. NSCLC is further subdivided into adenocarcinoma (the most common), squamous cell carcinoma (SCC), and large cell carcinoma. Furthermore, each subtype is likely to have specific mutations, which could be targeted for treatment. Medical imaging and radiomics feature extraction represent a candidate alternative to conventional tissue biopsy, a theory that is investigated in this study.
A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different...
Non-small Cell Lung CancerA single-center, non-interventional prospective observational study in the NSCLC patients with different driver genes